{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.35","value":"1.13"}]}],"title":"Core Score at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.27","value":"1.01"}]}],"title":"Severity Score at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.52","value":"0.97"}]}],"title":"Interference Score at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.67","value":"1.12"}]}],"title":"WAW Score at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.54","value":"0.81"}]}],"title":"REM Score at Cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Analyzed with descriptive analysis. The MDASI-MM scores measure the how severe the symptoms are, so higher scores are considered to be worse patient outcomes. Five subscales are derived from the 26 questions of the MDASI-MM questionnaire:\n\n1. mean core (13 MDASI core symptom items), ranges from 0 to 130.\n2. mean severity (13 MDASI core plus 7 MM-specific items), ranges from 0 to 200.\n3. mean interference (6 interference items), ranges from 0 to 60.\n4. mean WAW (interference with work, general activity, and walking), ranges from 0 to 30.\n5. mean REM (interference with relations with people, enjoyment of life, and mood), ranges from 0 to 30.\n\nhas context menu","dispersionType":"Standard Deviation","groups":[{"description":"Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Lenalidomide)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"through out study treatment and up to 30 days after completion of study treatment, up to 119 months","title":"M. D. Anderson Symptom Inventory (MDASI)-Myeloma Symptom Evaluation","type":"SECONDARY","unitOfMeasure":"scores on a scale"}